EP1030651A1 - Novel oral dosage form for carvedilol - Google Patents

Novel oral dosage form for carvedilol

Info

Publication number
EP1030651A1
EP1030651A1 EP98958546A EP98958546A EP1030651A1 EP 1030651 A1 EP1030651 A1 EP 1030651A1 EP 98958546 A EP98958546 A EP 98958546A EP 98958546 A EP98958546 A EP 98958546A EP 1030651 A1 EP1030651 A1 EP 1030651A1
Authority
EP
European Patent Office
Prior art keywords
carvedilol
formulation
release
coating
matrix
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98958546A
Other languages
German (de)
French (fr)
Other versions
EP1030651A4 (en
Inventor
Choon K. Oh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BOEHRINGER MANNHEIM PHARMACEUTICALS CORPORATION-SMITHKLINE BEECHAM Corp NO 1 LP
Roche Diagnostics Corp
Original Assignee
BOEHRINGER MANNHEIM PHARMACEUTICALS CORPORATION-SMITHKLINE BEECHAM Corp NO 1 LP
Boehringer Mannheim Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BOEHRINGER MANNHEIM PHARMACEUTICALS CORPORATION-SMITHKLINE BEECHAM Corp NO 1 LP, Boehringer Mannheim Pharmaceuticals Corp filed Critical BOEHRINGER MANNHEIM PHARMACEUTICALS CORPORATION-SMITHKLINE BEECHAM Corp NO 1 LP
Publication of EP1030651A1 publication Critical patent/EP1030651A1/en
Publication of EP1030651A4 publication Critical patent/EP1030651A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars

Definitions

  • the present invention relates to a novel formulation containing carvedilol, or a pharmaceutically acceptable salt thereof, and to its use in the treatment and/or prophylaxis of certain disorders.
  • U.S. Patent No 4,503,067 describes a compound which is known as carvedilol.
  • This compound is a novel multiple action drug useful in the treatment of mild to moderate hypertension.
  • Carvedilol is known to be both a competitive non-selective ⁇ -adrenoceptor antagonist and a vasodilator.
  • the vasodilatory actions of carvedilol result primarily from ⁇ i -adrenoceptor blockade, whereas the ⁇ -adrenoceptor blocking activity of the drug prevents reflex tachycardia when used in the treatment of hypertension.
  • These multiple actions of carvedilol are responsible for the antihypertensive efficacy of the drug.
  • carvedilol as a consequence of its antioxidant action in attenuating oxygen free radical- initiated lipid peroxidation, is useful in organ protection, in particular, cardioprotection. Additionally, carvedilol is useful in the treatment of congestive heart failure.
  • the current formulation of carvedilol is a conventional swallow tablet, taken twice daily.
  • This formulation is in immediate release form; that is to say the nature of the formulation is such that by the time carvedilol leaves the stomach, it is either in solution or it is in the form of a suspension of fine particles, i.e., a form from which carvedilol can be readily absorbed.
  • the present invention provides a controlled release or delayed release formulation containing carvedilol or a pharmaceutically acceptable salt thereof.
  • the present invention provides a controlled release or delayed release formulation comprising carvedilol, which is (l-(carbazol-4-yloxy-3-[[2-(o-methoxyphenoxy)- ethyl]amino]-2-propanol), of the formula (I): or a pharmaceutically acceptable salt thereof, in an oral dosage unit form.
  • carvedilol which is (l-(carbazol-4-yloxy-3-[[2-(o-methoxyphenoxy)- ethyl]amino]-2-propanol), of the formula (I): or a pharmaceutically acceptable salt thereof, in an oral dosage unit form.
  • the present invention also provides for a matrix formulation comprising carvedilol in an oral dosage unit form and for an enteric coated formulation comprising carvedilol in an oral dosage unit form.
  • Carvedilol may be conveniently prepared as described in U.S. Pat. No. 4,503.067. Reference should be made to said patent for its full disclosure, the entire disclosure of which is incorporated herein by reference.
  • carvedilol is suitably in the form of the free base or a pharmaceutically acceptable salt thereof.
  • carvedilol is in the form of the free base.
  • controlled release is meant any formulation that achieves slow release of drug over an extended period of time.
  • a portion of the carvedilol in the formualtion is made available as a priming dose and the remainder is released in a sustained fashion.
  • An example of a controlled release system is a matrix formulation.
  • delayed release any formulation that utilizes repetitive, intermittent dosings of carvedilol from one or more immediate release units incorporated into a single dosage form.
  • delayed release systems include repeat action tablets and capsules, and enteric-coated tablets where timed release is achieved by a barrier coating.
  • controlled release formulations which are suitable for incorporating carvedilol are described in:
  • delayed release formulations which are suitable for incorporating carvedilol are described in:
  • controlled release formulations containing carvedilol may be in the form of a non-compressed pellet, having an enteric coat or a sustained release coat permeable to gastrointestinal juices.
  • These controlled release formulations are prepared, for example, as described in U. S. Patent No. 4,524,060, issued June 18, 1985, and U. S. Patent No. 4,983,401, issued January 8, 1991.
  • Other controlled release formulations are described in U. S. Patent No. 4,880,830, issued November 14, 1989, and U. S. Patent No. 5,068,112, issued November 26, 1991.
  • Such controlled release formulations are preferably formulated in a manner such that release of carvedilol is affected predominantly during the passage through the stomach and the small intestine, and delayed release formulations are preferably formulated such that release of the carvedilol is avoided in the stomach and is affected predominantly during passage through the small intestine
  • Said formulations are preferably formulated such that the release of the carvedilol is predominantly l ⁇ z to 3 hours post ingestion.
  • the small intestine is suitably the duodenum, the ileum or the jejunem.
  • formulations of the present invention allow for once-a-day dosing.
  • the controlled release formulation may be a matrix formulation.
  • This formulation may comprise a plurality of matrix cores containing carvedilol, said matrix cores having different release rates of the drug.
  • the preferred formulation comprises an immediate release phase of carvedilol, as well as a sustained release phase.
  • the sustained release phase matrix core may be uncoated or coated. with a release-delaying substance.
  • the release-delaying substance when the matrix core is coated with a release- delaying substance, is present in an amount of from 2 to 30% (w/w) relative to the matrix core. More preferably, the release-delaying substance is present in an amount of from 5 to 25% (w/w).
  • the release-delaying substance of the present invention is a coating agent or a blend of agents thereof, which protects carvedilol from immediate degradation in the stomach.
  • the overcoating depending on the release rate desired, may allow for continual release, or slow release, or delayed release.
  • a preferred release-delaying substance is enteric coating, i.e., a medicinal preparation treated to pass through the stomach unaltered, which disintegrates in the intestines.
  • the matrix formulations of the present invention may be prepared using three types of materials: insoluble plastics, hydrophilic polymers or fatty compounds.
  • Plastic matrices include methyl acrylate-methacrylate, polyvinyl chloride and polyethylene.
  • Hydrophilic polymers include methylcellulose, hydroxypropylmethylcellulose (HMPC) and sodium carboxymethylcellulose.
  • Fatty compounds include various waxes such as carnauba wax and glyceryl tristearate. The most common method of preparation is to mix carvedilol with the matrix material and then compress the mixture into tablets. In the case of wax matrices, carvedilol is generally dispersed in molten wax, which is then congealed, granulated and compressed into cores.
  • the priming dose (the portion of the carvedilol that is immediately available in the formulation) is placed in a coat of the tablet.
  • the coat can be applied by press coating or by conventional pan or air suspension coating.
  • the carvedilol matrix tablet formulation comprises a mixture of HMPC and Carbopol.
  • the carvedilol matrix tablet formulation comprises a mixture of HMPC, Carbopol and mannitol.
  • carvedilol, mannitol, and HPMC is granulated with purified water, wet screened, and then dried. The dry granules are screened. The resultant internal granulation is blended with pre-screened Carbomer 941 until homogeneous. Pre-screened magnesium stearate is mixed with the blend to create the compression mix. Tablets are compressed as round cores and are coated to an approximate 3 % weight gain with an Opadry® white solution, followed by an approximate 0.5 % weight gain with an Opadry® clear solution.
  • the present invention also provides for various combinations of immediate release and controlled release forms.
  • the uncoated sustained release matrix core may be in combination with an immediate release form of carvedilol and/or a coated matrix form.
  • the matrix core may be comprised of a multitude of pellets coated independently with different release-delaying substances, all of which may be combined with uncoated or immediate release forms of carvedilol.
  • Delayed release formulations containing carvedilol may be prepared either by coating particles or granules of carvedilol with varying thicknesses of slowly soluble polymers, or by microencapsulation.
  • a hydrophilic substance acts as the coating material around a microcapsule.
  • the hydrophilic substance can be selected from a variety of natural and synthetic polymers including shellacs, waxes, starches, cellulose acetate phthlate or butyrate, polyvinylpyrrolidone and polyvinyl chloride. Once the coating material dissolves, all the carvedilol in the microcapsule is immediatley available for dissolution and absorption.
  • the release of carvedilol can be controlled by adjusting the thickness and the dissolution rate of the coat.
  • the thickness can be varied from less than 1 micromolar to 200 micromolar by changing the amount of coating material from 3 to 30% of the total weight. If only a few different thicknesses are used, usually three or four, carvedilol will be released at different predetermined times to give a delayed release effect, i.e., repeat action. If a spectrum of different thicknesses is employed, a more uniform blood level of carvedilol can be obtained.
  • the coated particles can be directly compressed into tablet, or placed in capsules. Carvedilol in the form of a controlled release or delayed release formulation can be used to treat hypertension, angina and congestive heart failure.
  • the formulations of the instant invention may also be used in organ protection, for example, in cardioprotection.
  • the present invention provides a method of treating hypertension, angina and congestive heart failure by administering an effective amount of a controlled release or delayed release formulation containing carvedilol or a pharmaceutically acceptable salt thereof, to a sufferer in need thereof.
  • the present invention further provides the use of a controlled release or delayed release formulation containing carvedilol or a pharmaceutically acceptable salt thereof in the manufacture of a medicament, for treating hypertension, angina and congestive heart failure.
  • the present invention also provides a pharmaceutical composition for use in the treatment of hypertension, angina and congestive heart failure which comprises a controlled release or delayed release formulation, preferably a matrix formulation, containing carvedilol or a pharmaceutically acceptable salt thereof. No unacceptable toxicological effects are expected when carvedilol is used according to the present invention.
  • Step 1 Weigh out the exact amounts of carvedilol, mannitol, hydroxypropyl methylcellulose, and purified water.
  • Step 2 Transfer the carvedilol, mannitol, and hydroxypropyl methylcellulose into a high shear mixer product bowl.
  • Step 3 Pre-blend ingredients for 2 minutes with the impeller and chopper at low speed setting.
  • Step 4 Granulate with purified water at low speed until desired granule appearance is achieved.
  • Step 5 Discharge granulation into stainless steel container for the wet- milling process.
  • Step 6 Slowly add the wet granules through the Quadro Comil (with screen) into a stainless steel container.
  • Step 7 Transfer the milled granulation to the pre-heated fluid bed product bowl.
  • Step 8 Dry the granules by maintaining the target inlet temperature of approximately 70°C (65°C - 75°C) until the product temperature reaches the target temperature (40 - 47°C) and the loss on drying is within the target range (0.5 - 1.8%).
  • Step 9 Set-up the Quadro Comil (variable speed) and attach the screen for milling.
  • Step 10 Add the dry granules through the Quadro Comil (with screen) into pre- tared polyethylene bags.
  • Step 11 Screen an excess amount of Carbomer 941 (Carbopol 97 IP) to de- aggregate by passing though a #20 mesh stainless steel screen by hand.
  • Step 12. Weigh out the exact amount of pre-screened Carbomer 941 (Carbopol 97 IP) onto the weigh paper.
  • Step 13 Weigh out the exact amount of carvedilol internal granulation into properly labelled polyethylene bags.
  • Step 14 Set-up a suitable size V-Blender.
  • Step 15 Transfer l/3rd of the carvedilol internal granulation into the V blender.
  • Step 16 Add l/3rd of the Carbomer 941 (Carbopol 971P) to the V blender.
  • Step 17 Repeat Steps 15 and 16 until all internal granulation and Carbomer 941 (Carbopol 97 IP) is in the V blender.
  • Step 18 Mix for 30 minutes or until homogeneous.
  • Step 19 Remove samples for in-process testing.
  • Step 20 Screen an excess amount of magnesium stearate (to de-aggregate) by passing though a #40 mesh stainless steel screen by hand.
  • Step 21 Weigh out the exact amount of pre-screened magnesium stearate onto the weigh paper.
  • Step 22 Load the magnesium stearate into the blender (containing the unlubricated granulation) and mix for 3 minutes.
  • Step 23 Transfer the compression mix to the hopper of a rotary tablet press using 7/16" x 5/8" round standard tooling.
  • Step 24 Compress tablets to meet the physical properties targets.
  • Step 25 Remove samples for in-process testing throughout the run.
  • Step 26 Separately weigh out the exact amount of carvedilol round active cores, Opadry® White and Opadry® Clear into polyethylene bags. If necessary, the round active cores may be bulked using oval placebo cores to achieve the batch size necessary to fill the coating pan.
  • Step 27 Transfer into a suitable, clean tared container, the required quantity of purified water to produce a 12% solids concentration of Opadry® White.
  • Step 28 With a vortex mixing action, slowly add the Opadry® White to the purified water. Continue mixing until no solid constituents are visible. Use this solution within 24 hours of manufacture.
  • Step 29 Transfer into a suitable, clean tared container, the required quantity of purified water to produce a 5 % solids concentration of Opadry® Clear.
  • Step 30 With a vortex mixing action, slowly add the Opadry® Clear to the
  • Step 31 Set-up the Accela Coater coating pan. Set pump to deliver white and clear coating solution to spray at a rate of approximately 35 g/minute.
  • Step 32 Transfer the cores to the coating pan. Pre heat the cores: Set the inlet temperature to 55°C (40°C - 70°C) while jogging the pan periodically. When product temperature reaches approximately 42°C (37°C - 45°C) start spray. Spray the entire quantity of white coating solution to obtain approximately a 3% weight gain coat. Under with clear coating solution to obtain approximately a 0.5% weight gain coat.
  • Step 33 Remove coated tablets from coating pan into double polyethylene-lined drum. If placebo cores were used to bulk up the coating batch size, a sorting/inspection process is performed after completion of the coating run, to separate the oval placebo cores from the round active cores.
  • Opadry White (OY-S-9603) NC 7.5 15.0 15.0
  • Tablet Coating (apply approximately 6-10% of tablet core weight) %w/w
  • Tablet Coating (apply approximately 6-10% of tablet core weight) %w/w
  • Tablet Coating (apply approximately 5-12% of tablet core weight) %w/w

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Indole Compounds (AREA)

Abstract

The present invention discloses a matrix formulation containing carvedilol.

Description

NOVEL ORAL DOSAGE FORM FOR CARVEDILOL
Field of the Invention
The present invention relates to a novel formulation containing carvedilol, or a pharmaceutically acceptable salt thereof, and to its use in the treatment and/or prophylaxis of certain disorders.
Background of the Invention
U.S. Patent No 4,503,067 describes a compound which is known as carvedilol. This compound is a novel multiple action drug useful in the treatment of mild to moderate hypertension. Carvedilol is known to be both a competitive non-selective β-adrenoceptor antagonist and a vasodilator. The vasodilatory actions of carvedilol result primarily from αi -adrenoceptor blockade, whereas the β-adrenoceptor blocking activity of the drug prevents reflex tachycardia when used in the treatment of hypertension. These multiple actions of carvedilol are responsible for the antihypertensive efficacy of the drug. Also, carvedilol, as a consequence of its antioxidant action in attenuating oxygen free radical- initiated lipid peroxidation, is useful in organ protection, in particular, cardioprotection. Additionally, carvedilol is useful in the treatment of congestive heart failure.
The current formulation of carvedilol is a conventional swallow tablet, taken twice daily. This formulation is in immediate release form; that is to say the nature of the formulation is such that by the time carvedilol leaves the stomach, it is either in solution or it is in the form of a suspension of fine particles, i.e., a form from which carvedilol can be readily absorbed.
It has now been found that controlled release and delayed release formulations containing carvedilol give rise to a once daily formulation. These formulations are able to extend the duration of action of carvedilol, thus improving the bioavailability of this drug.
Summary of the Invention
The present invention provides a controlled release or delayed release formulation containing carvedilol or a pharmaceutically acceptable salt thereof.
Detailed Description of the Invention
The present invention provides a controlled release or delayed release formulation comprising carvedilol, which is (l-(carbazol-4-yloxy-3-[[2-(o-methoxyphenoxy)- ethyl]amino]-2-propanol), of the formula (I): or a pharmaceutically acceptable salt thereof, in an oral dosage unit form.
The present invention also provides for a matrix formulation comprising carvedilol in an oral dosage unit form and for an enteric coated formulation comprising carvedilol in an oral dosage unit form.
Carvedilol may be conveniently prepared as described in U.S. Pat. No. 4,503.067. Reference should be made to said patent for its full disclosure, the entire disclosure of which is incorporated herein by reference.
According to the formulation of the instant invention, carvedilol is suitably in the form of the free base or a pharmaceutically acceptable salt thereof. Preferably, carvedilol is in the form of the free base.
By controlled release is meant any formulation that achieves slow release of drug over an extended period of time. In the controlled release formulations of the instant invention, a portion of the carvedilol in the formualtion is made available as a priming dose and the remainder is released in a sustained fashion. An example of a controlled release system is a matrix formulation.
By delayed release is meant any formulation that utilizes repetitive, intermittent dosings of carvedilol from one or more immediate release units incorporated into a single dosage form. Examples of delayed release systems include repeat action tablets and capsules, and enteric-coated tablets where timed release is achieved by a barrier coating. Examples of controlled release formulations which are suitable for incorporating carvedilol are described in:
Sustained Release Medications, Chemical Technology, Review No. 177, Ed. J.C. Johnson, Noyes Data Corporation (1980); and Controlled Drug Delivery, Fundamentals and Applications, 2nd Edition, Eds. J.R.
Robinson, V.H.L. Lee, Mercel Dekkes Inc., New York (1987).
Examples of delayed release formulations which are suitable for incorporating carvedilol are described in:
Remington's Pharmaceutical Sciences, 16th Edition, Ed. A. Osol, Mack Publishing Company (1980). Other examples of controlled release formulations which are suitable for incorporating carvedilol are described in U. S. Patent No. 4,839,177, issued June 13, 1989, and U. S. Patent No. 5,422,123, issued June 6, 1995. Matrix controlled release formulations for carvedilol are detailed in U. S. Patent No. 4,389,393, issued June 21, 1983, and U. S. Patent No. 4,968,508, issued November 6, 1990.
Additionally, the controlled release formulations containing carvedilol may be in the form of a non-compressed pellet, having an enteric coat or a sustained release coat permeable to gastrointestinal juices. These controlled release formulations are prepared, for example, as described in U. S. Patent No. 4,524,060, issued June 18, 1985, and U. S. Patent No. 4,983,401, issued January 8, 1991. Other controlled release formulations are described in U. S. Patent No. 4,880,830, issued November 14, 1989, and U. S. Patent No. 5,068,112, issued November 26, 1991.
Such controlled release formulations are preferably formulated in a manner such that release of carvedilol is affected predominantly during the passage through the stomach and the small intestine, and delayed release formulations are preferably formulated such that release of the carvedilol is avoided in the stomach and is affected predominantly during passage through the small intestine
Said formulations are preferably formulated such that the release of the carvedilol is predominantly l¥z to 3 hours post ingestion. The small intestine is suitably the duodenum, the ileum or the jejunem.
The formulations of the present invention allow for once-a-day dosing.
Preferred formulations for carvedilol are enteric coated tablets or caplets, wax or polymer coated tablets or caplets or time-release matrices, or combinations thereof. The oral route of administration of the formulation of the present invention is preferred. According to the instant invention, the controlled release formulation may be a matrix formulation. This formulation may comprise a plurality of matrix cores containing carvedilol, said matrix cores having different release rates of the drug. The preferred formulation comprises an immediate release phase of carvedilol, as well as a sustained release phase. The sustained release phase matrix core may be uncoated or coated. with a release-delaying substance. Preferably, when the matrix core is coated with a release- delaying substance, the release-delaying substance is present in an amount of from 2 to 30% (w/w) relative to the matrix core. More preferably, the release-delaying substance is present in an amount of from 5 to 25% (w/w).
The release-delaying substance of the present invention is a coating agent or a blend of agents thereof, which protects carvedilol from immediate degradation in the stomach. The overcoating, depending on the release rate desired, may allow for continual release, or slow release, or delayed release. A preferred release-delaying substance is enteric coating, i.e., a medicinal preparation treated to pass through the stomach unaltered, which disintegrates in the intestines.
The matrix formulations of the present invention may be prepared using three types of materials: insoluble plastics, hydrophilic polymers or fatty compounds. Plastic matrices include methyl acrylate-methacrylate, polyvinyl chloride and polyethylene. Hydrophilic polymers include methylcellulose, hydroxypropylmethylcellulose (HMPC) and sodium carboxymethylcellulose. Fatty compounds include various waxes such as carnauba wax and glyceryl tristearate. The most common method of preparation is to mix carvedilol with the matrix material and then compress the mixture into tablets. In the case of wax matrices, carvedilol is generally dispersed in molten wax, which is then congealed, granulated and compressed into cores. In the matrix formulation containing carvedilol, the priming dose (the portion of the carvedilol that is immediately available in the formulation) is placed in a coat of the tablet. The coat can be applied by press coating or by conventional pan or air suspension coating. In one embodiment of the invention, the carvedilol matrix tablet formulation comprises a mixture of HMPC and Carbopol. In a further embodiment of the invention, the carvedilol matrix tablet formulation comprises a mixture of HMPC, Carbopol and mannitol. The flow diagram hereinafter summarizes the manufacturing process for the preparation of controlled release tablets containing carvedilol.
Carvedilol
Mannitol
Blend
Hydroxypropyl methylcellulose
Purrlied Water Granulate
Wet Screen
Dry Granules
Screen
Carbomer 9 1 -Screen- Blend
Magnesium Stearate -Screen- Blend
Compression Mix
Compress Cores
Opadry White
-Mix- Spray Purified Water
Opadry Clear
-Mix- Spray Purified Water
Carvedilol Controlled Release Tablets
According to the instant invention, carvedilol, mannitol, and HPMC is granulated with purified water, wet screened, and then dried. The dry granules are screened. The resultant internal granulation is blended with pre-screened Carbomer 941 until homogeneous. Pre-screened magnesium stearate is mixed with the blend to create the compression mix. Tablets are compressed as round cores and are coated to an approximate 3 % weight gain with an Opadry® white solution, followed by an approximate 0.5 % weight gain with an Opadry® clear solution. The present invention also provides for various combinations of immediate release and controlled release forms. For example, the uncoated sustained release matrix core may be in combination with an immediate release form of carvedilol and/or a coated matrix form. The matrix core may be comprised of a multitude of pellets coated independently with different release-delaying substances, all of which may be combined with uncoated or immediate release forms of carvedilol.
Delayed release formulations containing carvedilol may be prepared either by coating particles or granules of carvedilol with varying thicknesses of slowly soluble polymers, or by microencapsulation. In formulations employing microencapsulation, a hydrophilic substance acts as the coating material around a microcapsule. The hydrophilic substance can be selected from a variety of natural and synthetic polymers including shellacs, waxes, starches, cellulose acetate phthlate or butyrate, polyvinylpyrrolidone and polyvinyl chloride. Once the coating material dissolves, all the carvedilol in the microcapsule is immediatley available for dissolution and absorption. Thus, the release of carvedilol can be controlled by adjusting the thickness and the dissolution rate of the coat. The thickness can be varied from less than 1 micromolar to 200 micromolar by changing the amount of coating material from 3 to 30% of the total weight. If only a few different thicknesses are used, usually three or four, carvedilol will be released at different predetermined times to give a delayed release effect, i.e., repeat action. If a spectrum of different thicknesses is employed, a more uniform blood level of carvedilol can be obtained. The coated particles can be directly compressed into tablet, or placed in capsules. Carvedilol in the form of a controlled release or delayed release formulation can be used to treat hypertension, angina and congestive heart failure. The formulations of the instant invention may also be used in organ protection, for example, in cardioprotection. The present invention provides a method of treating hypertension, angina and congestive heart failure by administering an effective amount of a controlled release or delayed release formulation containing carvedilol or a pharmaceutically acceptable salt thereof, to a sufferer in need thereof.
The present invention further provides the use of a controlled release or delayed release formulation containing carvedilol or a pharmaceutically acceptable salt thereof in the manufacture of a medicament, for treating hypertension, angina and congestive heart failure.
The present invention also provides a pharmaceutical composition for use in the treatment of hypertension, angina and congestive heart failure which comprises a controlled release or delayed release formulation, preferably a matrix formulation, containing carvedilol or a pharmaceutically acceptable salt thereof. No unacceptable toxicological effects are expected when carvedilol is used according to the present invention.
The examples which follow are not intended to limit the scope of this invention, but are provided to illustrate this invention. Many other embodiments will be readily apparent to those skilled in the art.
Examples
Manufacturing Process Description
BLENDING
Step 1. Weigh out the exact amounts of carvedilol, mannitol, hydroxypropyl methylcellulose, and purified water.
Step 2. Transfer the carvedilol, mannitol, and hydroxypropyl methylcellulose into a high shear mixer product bowl.
Step 3. Pre-blend ingredients for 2 minutes with the impeller and chopper at low speed setting.
GRANULATION
Step 4. Granulate with purified water at low speed until desired granule appearance is achieved.
Step 5. Discharge granulation into stainless steel container for the wet- milling process.
Step 6. Slowly add the wet granules through the Quadro Comil (with screen) into a stainless steel container.
Step 7. Transfer the milled granulation to the pre-heated fluid bed product bowl.
Step 8. Dry the granules by maintaining the target inlet temperature of approximately 70°C (65°C - 75°C) until the product temperature reaches the target temperature (40 - 47°C) and the loss on drying is within the target range (0.5 - 1.8%).
Step 9. Set-up the Quadro Comil (variable speed) and attach the screen for milling.
Step 10. Add the dry granules through the Quadro Comil (with screen) into pre- tared polyethylene bags.
UNLUBRICATED GRANULATION MIX
Step 11. Screen an excess amount of Carbomer 941 (Carbopol 97 IP) to de- aggregate by passing though a #20 mesh stainless steel screen by hand. Step 12. Weigh out the exact amount of pre-screened Carbomer 941 (Carbopol 97 IP) onto the weigh paper.
Step 13. Weigh out the exact amount of carvedilol internal granulation into properly labelled polyethylene bags.
Step 14. Set-up a suitable size V-Blender.
Step 15. Transfer l/3rd of the carvedilol internal granulation into the V blender.
Step 16. Add l/3rd of the Carbomer 941 (Carbopol 971P) to the V blender.
Step 17. Repeat Steps 15 and 16 until all internal granulation and Carbomer 941 (Carbopol 97 IP) is in the V blender.
Step 18. Mix for 30 minutes or until homogeneous.
Step 19. Remove samples for in-process testing.
LUBRICATED GRANULATION MIX
Step 20. Screen an excess amount of magnesium stearate (to de-aggregate) by passing though a #40 mesh stainless steel screen by hand.
Step 21. Weigh out the exact amount of pre-screened magnesium stearate onto the weigh paper.
Step 22. Load the magnesium stearate into the blender (containing the unlubricated granulation) and mix for 3 minutes.
COMPRESSION
Step 23. Transfer the compression mix to the hopper of a rotary tablet press using 7/16" x 5/8" round standard tooling.
Step 24. Compress tablets to meet the physical properties targets.
Step 25. Remove samples for in-process testing throughout the run.
COATING
Step 26. Separately weigh out the exact amount of carvedilol round active cores, Opadry® White and Opadry® Clear into polyethylene bags. If necessary, the round active cores may be bulked using oval placebo cores to achieve the batch size necessary to fill the coating pan.
Step 27. Transfer into a suitable, clean tared container, the required quantity of purified water to produce a 12% solids concentration of Opadry® White.
Step 28. With a vortex mixing action, slowly add the Opadry® White to the purified water. Continue mixing until no solid constituents are visible. Use this solution within 24 hours of manufacture. Step 29. Transfer into a suitable, clean tared container, the required quantity of purified water to produce a 5 % solids concentration of Opadry® Clear.
Step 30. With a vortex mixing action, slowly add the Opadry® Clear to the
Purified Water. Continue mixing until no solid constituents are visible. Use this solution within 24 hours of manufacture.
Step 31. Set-up the Accela Coater coating pan. Set pump to deliver white and clear coating solution to spray at a rate of approximately 35 g/minute.
Step 32. Transfer the cores to the coating pan. Pre heat the cores: Set the inlet temperature to 55°C (40°C - 70°C) while jogging the pan periodically. When product temperature reaches approximately 42°C (37°C - 45°C) start spray. Spray the entire quantity of white coating solution to obtain approximately a 3% weight gain coat. Follow with clear coating solution to obtain approximately a 0.5% weight gain coat.
Step 33. Remove coated tablets from coating pan into double polyethylene-lined drum. If placebo cores were used to bulk up the coating batch size, a sorting/inspection process is performed after completion of the coating run, to separate the oval placebo cores from the round active cores.
Example 1
Table 1: Unit Formulae for Controlled Release Carvedilol Formulations
Strength 50 mg 50 mg 50 mg
Formula BC BD BE
Component Compendia Quantity mg/tablet
Carvedilol 50.0 50.0 50.0
Mannitol USP 152.5 366.25 360.0
Hydroxypropyl Methycellulose USP 37.5 75.0 75.0
Carbomer 934P NF 7.5 3.75 10.0
Magnesium Stearate NF or Ph. Eur. 2.5 5.0 5.0
Opadry White (OY-S-9603) NC 7.5 15.0 15.0
Opadry Clear (YS-1-19025A) NC 1.25 2.5 2.5
Purified Water USP or Ph. Eur. q.s. q.s. q.s.
Total Tablet Weight 258.75 517.5 517.5 Example 2
Table 2: Typical Batch Formulae for Controlled Release Carvedilol
Formulations
Strength 50 mg 50 mg 50 mg
Formula BC BD BE
Component Compendia Quantity kg/batch
Carvedilol NC 1.36 0.68 0.68
Mannitol USP 4.14 4.96 4.87
Hydroxypropyl Methycellulose USP 1.01 1.01 1.01
Carbomer 934P NF 0.20 0.05 0.14
Magnesium Stearate NF or Ph. Eur. 0.07 0.07 0.07
Opadry White (OY-S-9603) NC 0.20 0.20 0.20
Opadry Clear (YS-1-19025A) NC 0.03 0.03 0.03
Purified Water USP or Ph. Eur. q.s. q.s. q.s.
Total Batch Weight (kg) 7.0 7.0 7.0
Batch Size (approx. number of 28,000 14,000 14,000 tablets)
Example 3 (pH Sensitive Coai t on Immediate Release Core)
Tablet Core %w/w
Carvedilol 11.45
Lactose 64.05
Microcrystalline Cellulose 20.0
Sodium Starch Glycollate 4.0
Magnesium Stearate 0.5
TOTAL 100.0
Tablet Coating (apply approximately 6-10% of tablet core weight) %w/w
Hydroxypropylmethylcellulose Phthalate 90.0 Triacetin 10.0 Example 4 (pH Sensitive Coat on Immediate Release Core)
Tablet Core as in Example 3
Tablet Coating (apply approximately 6-10% of tablet core weight) %w/w
Cellulose Acetate Phthalate 90.0
Diethyl Phthalate 10.0
Example 5 (Controlled Release Coating on Immediate Release Core)
Tablet Core as in Example 3
Tablet Coating (apply approximately 5-12% of tablet core weight) %w/w
Eudragit RS 100 86.0 Dibutyl Phthalate 10.0
Talc 4.0
FD&C Yellow No. 6 0.01
Example 6 (pH Sensitive Coat on Controlled Release Core)
Tablet Core as in Example 3
Tablet Coating as in Example 3
Example 7 (Encapsulated Controlled Release Coated Beads)
Pellet %w/w (approx)
Non Pareil Seed 30
Carvedilol 40
Gelatin 8
Lactose 20
Talc 2
Coating %w/w
Glycerylmonostearate 36.6
Glyceryldistearate 53.4
White Wax 10.0 The foregoing are illustrative of this invention. This invention, however, is not limited to the precise embodiments described herein, but encompasses all modifications within the scope of the claims which follow.
The various references to journals, patents, and other publications which are cited herein comprise the state of the art and are incorporated herein by reference as though fully set forth.

Claims

What is claimed is:
1. A matrix formulation comprising carvedilol in an oral dosage unit form.
2. The formulation of claim 1 which comprises a hydrophilic polymer.
3. The formulation of claim 2 wherein the hydrophilic polymer is hydroxypropy lmethylcellulose (HMPC) .
4. The formulation of claim 1 which comprises a mixture of HMPC and Carbopol.
5. The formulation of claim 1 which comprises a mixture of HMPC, Carbopol and mannitol.
6. An enteric coated formulation comprising carvedilol in an oral dosage unit form.
7. A method of treating hypertension, angina, or congestive heart failure which comprises administering carvedilol in a matrix formulation.
8. A method of treating hypertension, angina, or congestive heart failure which comprises administering carvedilol in an enteric coated formulation.
EP98958546A 1997-11-12 1998-11-12 Novel oral dosage form for carvedilol Withdrawn EP1030651A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6545697P 1997-11-12 1997-11-12
US65456P 1997-11-12
PCT/US1998/024102 WO1999024017A1 (en) 1997-11-12 1998-11-12 Novel oral dosage form for carvedilol

Publications (2)

Publication Number Publication Date
EP1030651A1 true EP1030651A1 (en) 2000-08-30
EP1030651A4 EP1030651A4 (en) 2006-05-31

Family

ID=22062830

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98958546A Withdrawn EP1030651A4 (en) 1997-11-12 1998-11-12 Novel oral dosage form for carvedilol

Country Status (14)

Country Link
EP (1) EP1030651A4 (en)
JP (1) JP2001522794A (en)
KR (1) KR20010031952A (en)
CN (1) CN1285738A (en)
AU (1) AU751117B2 (en)
BR (1) BR9814127A (en)
CA (1) CA2309542A1 (en)
HU (1) HUP0004345A3 (en)
IL (1) IL136028A0 (en)
NO (1) NO20002439L (en)
NZ (1) NZ504418A (en)
PL (1) PL340456A1 (en)
TR (1) TR200001362T2 (en)
WO (1) WO1999024017A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004041252A1 (en) 2002-11-08 2004-05-21 Egalet A/S Controlled release carvedilol compositions
AU2003288608A1 (en) * 2002-12-20 2004-07-14 Ranbaxy Laboratories Limited Controlled release, multiple unit drug delivery systems
US20050175695A1 (en) * 2003-11-25 2005-08-11 Catherine Castan Carvedilol free base, salts, anhydrous forms or solvates thereof, corresponding pharmaceutical compositions, controlled release formulations, and treatment or delivery methods
EP1686967A4 (en) * 2003-11-25 2012-08-08 Smithkline Beecham Cork Ltd Carvedilol free base, salts, anhydrous forms or solvates thereof, corresponding pharmaceutical compositions, controlled release formulations, and treatment or delivery methods
US20190083399A9 (en) * 2006-04-03 2019-03-21 Isa Odidi Drug delivery composition
TWI415604B (en) * 2009-09-29 2013-11-21 Tsh Biopharm Corp Ltd Controlled release carvediolol formulation
WO2011102505A1 (en) * 2010-02-22 2011-08-25 第一三共株式会社 Sustained-release solid preparation for oral use
WO2011102504A1 (en) 2010-02-22 2011-08-25 第一三共株式会社 Sustained-release solid preparation for oral use
TW201200165A (en) * 2010-02-22 2012-01-01 Daiichi Sankyo Co Ltd Oral solid extended release dosage form
CN104768552A (en) 2012-09-03 2015-07-08 第一三共株式会社 Hydromorphone hydrochloride-containing oral sustained-release pharmaceutical composition
KR102158339B1 (en) * 2016-02-05 2020-09-21 삼진제약주식회사 Carvedilol immediate release formulation having improved madescent
KR102525298B1 (en) 2020-12-30 2023-04-25 단국대학교 천안캠퍼스 산학협력단 Carvedilol loaded solid dispersion with increased oral bioavailability and methods for their preparation
KR102492147B1 (en) 2020-12-30 2023-01-26 단국대학교 천안캠퍼스 산학협력단 Carvedilol loaded solid oral compositions using self-nanoemulsifying drug delivery system and methods for their preparation

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998010754A1 (en) * 1996-09-12 1998-03-19 Roche Diagnostics Gmbh Fast decomposing pellets
US5760069A (en) * 1995-02-08 1998-06-02 Boehringer Mannheim Pharmaceuticals Corporation-Smithkline Beecham Corporation Limited Partnership #1 Method of treatment for decreasing mortality resulting from congestive heart failure

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2815926A1 (en) * 1978-04-13 1979-10-18 Boehringer Mannheim Gmbh NEW CARBAZOLYL- (4) -OXY-PROPANOLAMINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS
JPS5598120A (en) * 1979-01-16 1980-07-25 Shin Etsu Chem Co Ltd Preparation of drug having enteric coating
CA1146866A (en) * 1979-07-05 1983-05-24 Yamanouchi Pharmaceutical Co. Ltd. Process for the production of sustained release pharmaceutical composition of solid medical material
US4680323A (en) * 1983-12-01 1987-07-14 Hans Lowey Method and composition for the preparation of controlled long-acting pharmaceuticals for oral administration
EP0554306B1 (en) * 1990-10-23 1996-02-21 Davband Pty. Limited Back support for a chair or seat

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5760069A (en) * 1995-02-08 1998-06-02 Boehringer Mannheim Pharmaceuticals Corporation-Smithkline Beecham Corporation Limited Partnership #1 Method of treatment for decreasing mortality resulting from congestive heart failure
WO1998010754A1 (en) * 1996-09-12 1998-03-19 Roche Diagnostics Gmbh Fast decomposing pellets

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ROTE LISTE SERVICE GMBH: "Rote Liste 1997" 1997, ECV - EDITIO CANTOR , AULENDORF, GERMANY , XP002352847 * product entry no. 27 042 * *
See also references of WO9924017A1 *

Also Published As

Publication number Publication date
AU1456999A (en) 1999-05-31
TR200001362T2 (en) 2000-09-21
AU751117B2 (en) 2002-08-08
NO20002439D0 (en) 2000-05-11
IL136028A0 (en) 2001-05-20
WO1999024017A1 (en) 1999-05-20
CA2309542A1 (en) 1999-05-20
PL340456A1 (en) 2001-02-12
NZ504418A (en) 2003-02-28
HUP0004345A2 (en) 2001-06-28
EP1030651A4 (en) 2006-05-31
JP2001522794A (en) 2001-11-20
BR9814127A (en) 2000-10-03
CN1285738A (en) 2001-02-28
HUP0004345A3 (en) 2001-10-29
KR20010031952A (en) 2001-04-16
NO20002439L (en) 2000-05-11

Similar Documents

Publication Publication Date Title
US20040220250A1 (en) Novel oral dosage form for carvedilol
KR100535954B1 (en) Enteric coated pharmaceutical tablet and method of manufacturing
US8968777B2 (en) Tranexamic acid formulations with reduced adverse effects
FI78835B (en) FOERFARANDE FOER FRAMSTAELLNING AV EN NY DIPYRIDAMOL-RETARDFORM.
EP0305051B1 (en) Orally sustained-release acetaminophen formulation and process to obtain it
NZ201008A (en) Oral preparations containing dipyridamole and at least 5 molar equivalents of orally acceptable acidic excipient
AU2003260336C1 (en) Sustained release formulations comprising lamotrigine
EP1233768A1 (en) Carvedilol methanesulfonate
JP2015098477A (en) Compositions comprising weakly basic drugs and controlled-release dosage forms
CA2130595A1 (en) Controlled release-initiation and controlled release-rate pharmaceutical composition
IE81099B1 (en) Slow-release pharmaceutical composition
HU206044B (en) Process for producing compositions with controlled release of dihydropyridine derivatives as active ingredient
JPH0122245B2 (en)
AU751117B2 (en) Novel oral dosage form for carvedilol
KR20010080578A (en) Pharmaceutical combination preparations
US20030099710A1 (en) Granule modulating hydrogel system
CA2478425A1 (en) Medicaments containing active ingredients which lower the level of cholesterol with time-delayed active ingredient release
US4938966A (en) Controlled release flecainide acetate formulation
MXPA00004573A (en) Novel oral dosage form for carvedilol
CZ20001720A3 (en) Novel oral dosage form for carvedilol
CA3226799A1 (en) Multiparticulate pharmaceutical composition
US20040228918A1 (en) Granule modulating hydrogel system
MXPA00011974A (en) Enteric coated pharmaceutical tablet and method of manufacturing

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000515

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: SI PAYMENT 20000515

A4 Supplementary search report drawn up and despatched

Effective date: 20060419

17Q First examination report despatched

Effective date: 20061020

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20070301